First laser ions at the CERN-MEDICIS facility

Gadelshin, Vadim; Wilkins, S. G.; Fedosseev, Valentin; Barbero, E.; Barozier, Vincent; Bernardes, A. P.; Chevallay, E.; Cocolios, T. E.; Crepieux, B.; Dockx, Kristof; Eck, Matthias; Fernier, P.; Cavaier, Roberto Formento; Haddad, Férid; Jakobi, Johannes; Lambert, Laura; Marsh, B. A.; Marzari, S.; Ramos, J.P.; Moberg, Annie Ringvall; Rothe, S.; Stora, T.; Studer, Dominik; Suarez, Andres Vieitez; Weber, Felix; Wendt, Κ.

doi:10.1007/s10751-020-01718-y

Cited by 6 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the parallel ionization of bulk amounts of 168 Er can reduce the ion source performance, impeding the proper separator adjustment. This can be solved with the application of an isotope-selective laser ionization scheme or optimization of the mass separator for high-flux ion-beam operation ( 40 ).…”

Section: Discussionmentioning

confidence: 99%

“…Neutron-deficient diagnostic and therapeutic terbium radionuclides [ 152 Tb (19,20,(26)(27)(28)(29), 155 Tb (27,30), and 149 Tb (21,27,31,32)], were separated at ISOLDE and, after chemical separation at PSI, utilized for pre-clinical in vitro and in vivo studies. Similar mass separation techniques have recently been used at the CERN-MEDICIS facility with off-line mass separation capabilities (33)(34)(35)(36)(37)(38)(39)(40). An 169 Er mass separation proof of concept (up to 17 MBq), obtained from reactor-irradiated enriched 168 Er targets, was previously performed using an electromagnetic isotope separation (EMIS) method (37).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

et al. 2021

Self Cite

View full text Add to dashboard Cite

The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…A detailed technical overview of the MEDICIS separator, being the principal infrastructure of the presented work, is given in ( 35 ). The dedicated MEDICIS resonance ionization laser ion source system MELISSA ( 36 , 37 ), resembling the solid-state laser system of ISOLDE RILIS ( 38 ), provides laser beams for element selective ionization by 10 kHz repetition rate wavelength-tunable Ti:sapphire lasers pumped by commercial frequency-doubled diode-pumped Nd:YAG lasers (Innolas Nanio).…”

Section: Experimental Setup and Methodsmentioning

confidence: 99%

Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS

et al. 2021

Self Cite

View full text Add to dashboard Cite

Thulium-167 is a promising radionuclide for nuclear medicine applications with potential use for both diagnosis and therapy (“theragnostics”) in disseminated tumor cells and small metastases, due to suitable gamma-line as well as conversion/Auger electron energies. However, adequate delivery methods are yet to be developed and accompanying radiobiological effects to be investigated, demanding the availability of 167Tm in appropriate activities and quality. We report herein on the production of radionuclidically pure 167Tm from proton-irradiated natural erbium oxide targets at a cyclotron and subsequent ion beam mass separation at the CERN-MEDICIS facility, with a particular focus on the process efficiency. Development of the mass separation process with studies on stable 169Tm yielded 65 and 60% for pure and erbium-excess samples. An enhancement factor of thulium ion beam over that of erbium of up to several 104 was shown by utilizing laser resonance ionization and exploiting differences in their vapor pressures. Three 167Tm samples produced at the IP2 irradiation station, receiving 22.8 MeV protons from Injector II at Paul Scherrer Institute (PSI), were mass separated with collected radionuclide efficiencies between 11 and 20%. Ion beam sputtering from the collection foils was identified as a limiting factor. In-situ gamma-measurements showed that up to 45% separation efficiency could be fully collected if these limits are overcome. Comparative analyses show possible neighboring mass suppression factors of more than 1,000, and overall 167Tm/Er purity increase in the same range. Both the actual achieved collection and separation efficiencies present the highest values for the mass separation of external radionuclide sources at MEDICIS to date.

show abstract

“…More information regarding the MEDICIS beam line can be found in (15). Furthermore, the MELISSA laser laboratory (16,17) helps to increase the separation efficiency and the selectivity. The extracted radionuclides are usually implanted onto thin zinccoated gold foils.…”

Section: Medicis' Modes Of Operation For Radionuclide Productionmentioning

confidence: 99%

“…It was followed by the successful commissioning of the shielded fume hood in March into which the collection foils can be safely removed from their support, and where radiochemistry developments can be performed. Another milestone was reached in 2019 when the MELISSA laboratory (16,17) became fully operational in April. The installed laser setup consisted of two Z-cavity Ti:sapphire lasers of the Mainz University/CERN design pumped by two 10 kHz pulsed Nd:YAG lasers InnoLas Nanio 532-18-Y (see Figure 6).…”

Section: : a Year Without Protons At Cern Compensated By The Use Of Externally Irradiated Target Materialsmentioning

confidence: 99%

CERN-MEDICIS: A Review Since Commissioning in 2017

Duchemin¹,

Ramos²,

Stora³

et al. 2021

Front. Med.

Self Cite

View full text Add to dashboard Cite

The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and development in nuclear medicine using non-conventional radionuclides. Since then, fourteen institutes, including CERN, have joined the collaboration to drive the scientific program of this unique installation and evaluate the needs of the community to improve the research in imaging, diagnostics, radiation therapy and personalized medicine. The facility has been built as an extension of the ISOLDE (Isotope Separator On Line DEvice) facility at CERN. Handling of open radioisotope sources is made possible thanks to its Radiological Controlled Area and laboratory. Targets are being irradiated by the 1.4 GeV proton beam delivered by the CERN Proton Synchrotron Booster (PSB) on a station placed between the High Resolution Separator (HRS) ISOLDE target station and its beam dump. Irradiated target materials are also received from external institutes to undergo mass separation at CERN-MEDICIS. All targets are handled via a remote handling system and exploited on a dedicated isotope separator beamline. To allow for the release and collection of a specific radionuclide of medical interest, each target is heated to temperatures of up to 2,300°C. The created ions are extracted and accelerated to an energy up to 60 kV, and the beam steered through an off-line sector field magnet mass separator. This is followed by the extraction of the radionuclide of interest through mass separation and its subsequent implantation into a collection foil. In addition, the MELISSA (MEDICIS Laser Ion Source Setup At CERN) laser laboratory, in service since April 2019, helps to increase the separation efficiency and the selectivity. After collection, the implanted radionuclides are dispatched to the biomedical research centers, participating in the CERN-MEDICIS collaboration, for Research & Development in imaging or treatment. Since its commissioning, the CERN-MEDICIS facility has provided its partner institutes with non-conventional medical radionuclides such as Tb-149, Tb-152, Tb-155, Sm-153, Tm-165, Tm-167, Er-169, Yb-175, and Ac-225 with a high specific activity. This article provides a review of the achievements and milestones of CERN-MEDICIS since it has produced its first radioactive isotope in December 2017, with a special focus on its most recent operation in 2020.

show abstract

First laser ions at the CERN-MEDICIS facility

Cited by 6 publications

References 26 publications

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS

CERN-MEDICIS: A Review Since Commissioning in 2017

Contact Info

Product

Resources

About